1. Home
  2. ETR vs ALNY Comparison

ETR vs ALNY Comparison

Compare ETR & ALNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Entergy Corporation

ETR

Entergy Corporation

HOLD

Current Price

$115.67

Market Cap

52.4B

Sector

Utilities

ML Signal

HOLD

Logo Alnylam Pharmaceuticals Inc.

ALNY

Alnylam Pharmaceuticals Inc.

HOLD

Current Price

$339.03

Market Cap

42.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ETR
ALNY
Founded
1949
2002
Country
United States
United States
Employees
N/A
115
Industry
Electric Utilities: Central
Biotechnology: Pharmaceutical Preparations
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
52.4B
42.1B
IPO Year
2005
2004

Fundamental Metrics

Financial Performance
Metric
ETR
ALNY
Price
$115.67
$339.03
Analyst Decision
Buy
Strong Buy
Analyst Count
16
28
Target Price
$111.13
$471.00
AVG Volume (30 Days)
2.6M
1.1M
Earning Date
04-29-2026
04-30-2026
Dividend Yield
2.22%
N/A
EPS Growth
59.59
206.88
EPS
3.91
2.33
Revenue
$12,946,686,000.00
$1,037,418,000.00
Revenue This Year
$8.28
$52.99
Revenue Next Year
$8.14
$31.77
P/E Ratio
$29.48
$142.78
Revenue Growth
8.98
22.88
52 Week Low
$79.48
$225.84
52 Week High
$117.81
$495.55

Technical Indicators

Market Signals
Indicator
ETR
ALNY
Relative Strength Index (RSI) 68.28 57.99
Support Level $91.91 $304.36
Resistance Level N/A $345.90
Average True Range (ATR) 2.35 10.85
MACD 0.48 2.27
Stochastic Oscillator 86.68 86.32

Price Performance

Historical Comparison
ETR
ALNY

About ETR Entergy Corporation

Entergy is a holding company with five regulated vertically integrated utilities that generate and distribute electricity to 3 million customers in Arkansas, Louisiana, Mississippi, and Texas. It is one of the largest power producers in the country with 27 gigawatts of rate-regulated owned and leased power generation capacity. Entergy was the second-largest nuclear owner in the US before it began retiring and selling its plants in the Northeast in 2014. It sold its two small gas utilities in Louisiana in 2025.

About ALNY Alnylam Pharmaceuticals Inc.

Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway in cells that enables sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.

Share on Social Networks: